HAP Trading’s Arcturus Therapeutics ARCT Stock Holding History

HAP Trading’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-23,500	Closed	-$80K	–	2201
2021 Q4	$80K	Buy	+23,500	New	+$958K	﹤0.01%	1302
2021 Q1	–	Sell	-143,100	Closed	-$318K	–	1908
2020 Q4	$318K	Buy	+143,100	New	+$9.69M	0.01%	781
2017 Q1	–	Sell	-2,329	Closed	-$7K	–	1040
2016 Q4	$7K	Buy	+2,329	New	+$34.8K	﹤0.01%	872
2014 Q4	–	Sell	-3,200	Closed	-$57K	–	1042
2014 Q3	$57K	Buy	+3,200	New	+$417K	﹤0.01%	740

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

HAP Trading's ARCT Position: Q3 2025 in Review

HAP Trading opened a new position in Arcturus Therapeutics (ARCT) in Q3 2025: 77,142 shares worth $1.42M. The stake represents 0.1% of the portfolio and ranks #135 among its holdings.

136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

HAP Trading held 77,142 shares of Arcturus Therapeutics worth $1.42M as of Q3 2025.
Arcturus Therapeutics was a new HAP Trading position in Q3 2025.
Arcturus Therapeutics made up 0.1% of HAP Trading's portfolio in Q3 2025, its #135 holding.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on HAP Trading's 13F filing for Q3 2025, filed 12 Nov 2025.